CStone Pharmaceuticals (SEHK:2616) Valuation Spotlight After Key Pipeline Advances and IND Milestone

Simply Wall St.11-17

CStone Pharmaceuticals (SEHK:2616) is in focus after two important pipeline updates landed this week. The company will showcase preclinical data for its CS2015 antibody at ACAAI 2025. In addition, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584939643?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-11-17 14:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584939643","market":"sg","top_or_hot":-1,"title":"CStone Pharmaceuticals (SEHK:2616) Valuation Spotlight After Key Pipeline Advances and IND Milestone","media":"Simply Wall St.","content":"<div>\n<p>CStone Pharmaceuticals (SEHK:2616) is in focus after two important pipeline updates landed this week. The company will showcase preclinical data for its CS2015 antibody at ACAAI 2025. In addition, ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-valuation-spotlight-after-ke\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CStone Pharmaceuticals (SEHK:2616) Valuation Spotlight After Key Pipeline Advances and IND Milestone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCStone Pharmaceuticals (SEHK:2616) Valuation Spotlight After Key Pipeline Advances and IND Milestone\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-17 14:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-valuation-spotlight-after-ke><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CStone Pharmaceuticals (SEHK:2616) is in focus after two important pipeline updates landed this week. The company will showcase preclinical data for its CS2015 antibody at ACAAI 2025. In addition, ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-valuation-spotlight-after-ke\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-valuation-spotlight-after-ke","article_id":"2584939643","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/cstone-pharmaceuticals-sehk2616-valuation-spotlight-after-ke","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2584939643","pubTimestamp":1763359927,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CStone Pharmaceuticals (SEHK:2616) is in focus after two important pipeline updates landed this week. The company will showcase preclinical data for its CS2015 antibody at ACAAI 2025. In addition, CS2009 has cleared an IND milestone in China.\nSee our latest analysis for CStone Pharmaceuticals.\nCStone’s share price has surged 148% year-to-date and delivered an exceptional 227% total shareholder return over the past year. This performance has been fueled in recent days by promising advances in...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","02616":"基石药业-B"},"translate_title":"基石药业（SEHK：2616）在关键管线进展和IND里程碑后估值成为焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":0.9,"DCF":1},"content_text":"CStone Pharmaceuticals (SEHK:2616) is in focus after two important pipeline updates landed this week. The company will showcase preclinical data for its CS2015 antibody at ACAAI 2025. In addition, CS2009 has cleared an IND milestone in China. See our latest analysis for CStone Pharmaceuticals. CStone’s share price has surged 148% year-to-date and delivered an exceptional 227% total shareholder return over the past year. This performance has been fueled in recent days by promising advances in both its oncology and autoimmune pipelines. Momentum has swung sharply back into the positive following the announcement of a major clinical milestone and a forthcoming international conference presentation. Looking for more opportunities in healthcare? Now is an ideal time to explore innovation leaders through our discovery of See the full list for free. With CStone’s rapid gains driven by anticipation of its clinical milestones, the question for investors now is whether the current price still undervalues future potential, or if recent success is already factored in by the market. AdvertisementPrice-to-Sales of 40.4x: Is it justified? CStone Pharmaceuticals currently trades at a steep price-to-sales ratio of 40.4x, noticeably higher than both its peers and the sector norm, despite its recent gains to HK$6.08 per share. The price-to-sales ratio gives investors an idea of how much they are paying for each dollar of revenue. For biotechs like CStone, which are often in high-growth phases but not yet consistently profitable, this multiple is a widely watched benchmark because earnings-based ratios may not be meaningful. However, at 40.4x, CStone’s price-to-sales is significantly higher than the Hong Kong Biotechs industry average of 14x as well as the peer group average of 17.6x. Furthermore, the fair value price-to-sales ratio, based on a regression analysis considering fundamentals, is just 3.5x. This suggests that the market is pricing in very bullish expectations that may need to be reassessed if growth targets are not met. Explore the SWS fair ratio for CStone Pharmaceuticals Result: Price-to-Sales of 40.4x (OVERVALUED) However, setbacks in clinical trial progress or slower than expected revenue growth may quickly dampen investor enthusiasm and challenge current valuations. Find out about the key risks to this CStone Pharmaceuticals narrative. Another View: SWS DCF Model Signals Deep Value While the current price-to-sales ratio looks high, our DCF model paints a strikingly different picture. According to this method, CStone Pharmaceuticals is trading 71.9% below its estimated fair value of HK$21.61. This suggests it could be significantly undervalued. When fundamentally-derived estimates differ so much from multiples, which outlook will markets believe? Look into how the SWS DCF model arrives at its fair value. 2616 Discounted Cash Flow as at Nov 2025Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CStone Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 897 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own CStone Pharmaceuticals Narrative If you want to dig deeper, challenge these results, or simply follow your own process, you can piece together your personal story in a few minutes, Do it your way. A great starting point for your CStone Pharmaceuticals research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision. Want Even More Investment Ideas? Don't let your next big winner slip away. Take your portfolio further by finding unique growth opportunities, hidden undervalued gems, and innovative themes with our powerful screener tools.  Boost your search for overlooked value by spotting gems among these 897 undervalued stocks based on cash flows whose cash flows hint at untapped potential. Capitalize on the AI revolution by targeting emerging market leaders with these 25 AI penny stocks before everyone else gets on board. Lock in regular income and stability through high-yield choices with these 16 dividend stocks with yields > 3% for your long-term strategy.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584939643","isCrawlerRequest":true}